IL-17 receptor antagonist
This page covers all IL-17 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting IL-17 receptor.
Targets
Phase 2 pipeline (1)
- DC-806 · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Inflammatory diseases
DC-806 is an anti-inflammatory monoclonal antibody targeting the IL-17 receptor.